stockrowVAXART, INC.
VXRT Healthcare Biotechnology
VAXART, INC.’s revenue for fiscal 2025 (year ended December 2025) was $237.3 million, up 726.7% from fiscal 2024.
- Revenue
- −85.3%
- EPS
- −75.0%
- Free cash flow
- −57.2%
Quarter to September 2026, against a year earlier
Follow VXRT
Alert me
VAXART, INC. (VXRT) EV/Sales
As of 5 November 2026, VAXART, INC. (VXRT) trades at a EV/Sales of 0.1×. Over the past ten years it has ranged from −39.1× (December 2022) to 1,099× (April 2022); the current reading is higher than 23% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.1× | (97.38%) |
| FY2024 | 2.9× | (57.22%) |
| FY2023 | 6.7× | (89.91%) |
| FY2022 | 66.9× | (89.99%) |
| FY2021 | 668× | 614.53% |
| FY2020 | 93.5× | — |
| FY2019 | −0.5× | — |
| FY2018 | 0.6× | (92.35%) |
| FY2017 | 7.3× | — |
| FY2017 | −4.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 0.2× | (28.88%) |
| Jun 2026 | 0.3× | 2.70% |
| Mar 2026 | 0.3× | 349.41% |
| Dec 2025 | 0.1× | (79.52%) |
| 39 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SEER Seer, Inc. compare | −4.4× |
| MIST Milestone Pharmaceuticals Inc. compare | −3.0× |
| PLYX Polaryx Therapeutics, Inc. compare | n/m |
| KZIA Novogen Limited compare | n/m |
| VXRT VAXART, INC. | 0.1× |
| EQ Equillium, Inc. compare | 2.4× |
| ICCC ImmuCell Corporation compare | 2.9× |
| VTVT vTv Therapeutics Inc. compare | 4.9× |
| CBUS Cibus, Inc. compare | 16.0× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)